Click and press the play button in the chart above to see what I will be watching.
- Broke out of wedge , nice upside potential
- gap is already filled, should re-test that level and break above.
- ADX indicating strong upside trend
- on a pullback, previous resistance, top of wedge (price marked) should become support.
- Next level of serious resistance is $9.10 -> $9.80 then $10++++
CEO buying $350K insider buying is very bullish and has sparked investor confidence. TGTX has potential MZL data due soon and Multiple Sclerosis next year. This is a great sign to enter 2nd half. Read Chris Stang’s analysis on TGTX!!
Discloser: I am long TGTX , this is not a note to buy or sell. Please do you homework before investing.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.